What to Expect When Starting Tirzepatide (Mounjaro)
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Introduction
Mounjaro (tirzepatide) is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus [1]. Administered as a once-weekly subcutaneous injection, it works by activating both GIP and GLP-1 receptors — enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central mechanisms [2]. The dual-agonist mechanism produces greater glycemic control and weight loss than single GLP-1 receptor agonists in head-to-head trials.
Week-by-week timeline
Starting at 2.5 mg Weekly
You will begin with 2.5 mg injected once weekly. This is a tolerability dose, not yet at a therapeutic level [1]. GI side effects are the most common: nausea (12-18%), diarrhea (12-17%), decreased appetite (6-11%), and vomiting (5-9%) — generally peaking in the first 1-2 weeks at each new dose level [2]. You may notice a reduced appetite and modest blood sugar improvement even at this starting dose. Injection site reactions (redness, itching) occur in about 3-5% of patients.
First Escalation to 5 mg Weekly
After 4 weeks, the dose increases to 5 mg weekly — the first therapeutic dose [1]. GI symptoms may briefly recur or intensify. Blood sugar control will improve more noticeably. The SURPASS-2 trial showed a mean HbA1c reduction of 2.0% at the 5 mg dose, already exceeding many comparator drugs [3]. Weight loss becomes more apparent — average weight reduction of 5-7 kg is typical at therapeutic doses in diabetes trials. Your doctor may adjust other diabetes medications to prevent hypoglycemia.
Continued Escalation to 10-15 mg
The dose may be escalated in 2.5 mg increments every 4 weeks, up to a maximum of 15 mg weekly [1]. Each escalation may cause temporary GI symptoms. The SURPASS trials demonstrated HbA1c reductions of 2.0-2.6% and weight loss of 7-13 kg at higher doses — superior to semaglutide 1 mg in the SURPASS-2 head-to-head trial [3]. Your HbA1c should be showing significant improvement, and weight loss will continue to accumulate. Energy levels often improve as glycemic control and body weight normalize.
Maintenance at Target Dose
Once the target dose is reached and HbA1c is at goal (typically <7%), the dose is maintained [1]. GI side effects have usually resolved. Weight loss continues for 12-18 months before plateauing. The SURPASS-4 trial showed cardiovascular safety with tirzepatide, and further cardiovascular outcome data is anticipated [2]. Regular monitoring includes HbA1c (every 3-6 months), kidney function, and assessment of other diabetes medications that may need adjustment.
When to call your doctor
Contact your healthcare provider if you experience:
- Severe, persistent abdominal pain — especially if radiating to the back, which may indicate pancreatitis [1]
- Signs of allergic reaction: rash, itching, swelling of face/lips/tongue, difficulty breathing [1]
- Persistent vomiting or inability to keep down fluids for more than 24 hours, risking dehydration and kidney injury [1]
- Symptoms of hypoglycemia (especially if also taking insulin or sulfonylureas): shakiness, sweating, confusion, rapid heartbeat, blurred vision [1]
- A lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath — tirzepatide carries a boxed warning about thyroid C-cell tumors observed in rodent studies [1]
Tips for getting started
Inject Mounjaro on the same day each week, at any time of day, with or without meals. Rotate injection sites (abdomen, thigh, upper arm) to prevent lipodystrophy. Eat smaller, more frequent meals and avoid high-fat or greasy foods to minimize nausea, especially during dose escalation [1]. Stay well hydrated. Store unused pens in the refrigerator; the pen in use can be kept at room temperature for up to 21 days. If you also take insulin, use separate injection sites and discuss dose adjustments with your doctor to avoid hypoglycemia [2]. Prioritize protein-rich foods to preserve lean muscle during weight loss.
Frequently asked questions
More about Tirzepatide (Mounjaro)
References
- [Regulatory] Mounjaro (tirzepatide) FDA Prescribing Information. Eli Lilly. Revised 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215866s007lbl.pdf Accessed 2025-01-15.
- [Regulatory] Tirzepatide. StatPearls [Internet]. National Library of Medicine. Updated 2024. https://www.ncbi.nlm.nih.gov/books/NBK585056/ Accessed 2025-01-15.
- [Clinical] Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. https://pubmed.ncbi.nlm.nih.gov/34170647/ Accessed 2025-01-15.
Written and fact-checked by PrescriptionDrugs.org Editorial Team
Last updated: